How long should I wait between peptide cycles?
It depends on the peptide class. Recovery and most GH peptides need 4-8 weeks off. IGF-1 LR3 needs 4-8 weeks minimum. Topical GHK-Cu can run continuously.
Updated May 8, 2026 · 5 min read
The off period depends on the peptide class. Recovery peptides (BPC-157, TB-500): 4-8 weeks off. Short-acting GH secretagogues: 4-8 weeks. Long-acting GH (CJC DAC, MK-677): 8+ weeks. IGF-1 LR3: 4-8 weeks minimum. MOTS-c: 4-8 weeks. Topical GHK-Cu: continuous use is acceptable. The general rule: the off period should be at least 50% of the on period, and never less than 5 half-lives of the peptide.
There isn't one number that applies to everything. The reasoning behind each off period is different: receptor desensitization, side-effect recovery, theoretical safety, or just clearance time for long-acting compounds.
The reference table
| Peptide class | Typical cycle | Off period | Why |
|---|---|---|---|
| BPC-157, TB-500 | 4-8 weeks | 4-8 weeks | Avoid chronic angiogenic signaling; let goal-achievement dictate restart |
| Short-acting GH secretagogues (Ipa, CJC no-DAC, Sermorelin) | 12-16 weeks | 4-8 weeks | Restore normal-physiology window for GH axis |
| Long-acting GH secretagogues (CJC DAC) | 12 weeks | 8+ weeks | Long half-life means first 4-5 weeks of "off" are clearance |
| MK-677 | 8-12 weeks | 4-8 weeks | Insulin-sensitivity drift recovery |
| IGF-1 LR3 | 4-6 weeks | 4-8 weeks | Receptor desensitization plus cancer-axis caveats |
| MOTS-c | 8-12 weeks | 4-8 weeks | Match metabolic adaptation timeline |
| GHK-Cu (topical) | Continuous OK | — | Cosmetic-grade, decades of safety data |
| GHK-Cu (injection) | 6-12 weeks | 4 weeks | Less data on chronic injectable use |
| Tesamorelin | Per indication | Per indication | FDA-approved for HIV-LD; otherwise cycle |
For more detail by peptide, see cycle length by peptide class.
Recovery peptides — 4-8 weeks off
BPC-157 and TB-500 are tools for specific repair goals. The off period serves two purposes:
- Lets you find out what was actually the peptide vs. what was your training and recovery improving anyway. This is what cycling is for — establishing causation.
- Avoids continuous angiogenic signaling. Pre-clinical models for these peptides are healing models, not chronic preventive use. Continuous angiogenic signaling has theoretical (not demonstrated) cancer concerns.
The 4-8 week range covers most cases:
| Sub-pattern | When |
|---|---|
| 4 weeks off | After a 4-6 week cycle for an acute injury |
| 6-8 weeks off | After an 8-week stack cycle for chronic tendinopathy |
| 8+ weeks off | After back-to-back cycles or aggressive dosing |
Short-acting GH secretagogues — 4-8 weeks off
Ipamorelin, CJC-1295 without DAC, and Sermorelin all preserve the natural pulsatile pattern of GH release. The pituitary is still in charge. Receptor desensitization is less of a concern than with long-acting forms.
The off period here is more about giving the GH axis a normal-physiology window than about avoiding tachyphylaxis. 4-8 weeks is the typical range; 4 weeks for shorter cycles, 8 weeks for the full 12-16 week run.
Long-acting GH secretagogues — 8+ weeks off
CJC-1295 with DAC and MK-677 produce sustained elevation rather than discrete pulses. This pattern is more prone to:
- Receptor downregulation
- Side-effect drift (water retention, fasting glucose elevation)
- Cumulative metabolic shifts
The 8+ week off period reflects two things: the long half-life of CJC DAC (about 7 days, so the first 4-5 weeks of "off" are residual peptide clearing), and the time needed for desensitized receptors and metabolic markers to recover. For MK-677, fasting glucose drift can take 4-8 weeks to revert toward baseline.
IGF-1 LR3 — 4-8 weeks minimum
The cancer-axis caveats matter here. IGF-1 LR3 elevates the same signaling pathway implicated in IGF-1-related cancer-progression concerns. Cycling reduces total exposure; longer off periods reduce it further.
Beyond the safety reasoning, IGF-1 receptor desensitization is documented — running back-to-back cycles produces less effect at the same dose. The 4-8 week minimum off applies; some users run 8-12 weeks off between IGF-1 LR3 cycles for the cumulative-exposure reasoning.
MOTS-c — 4-8 weeks off
The 4-8 week off period matches the metabolic adaptation timeline. MOTS-c works through AMPK activation and mitochondrial efficiency improvements. Those effects take weeks to express and weeks to revert.
What "off" actually means
A few practical clarifications:
| Misconception | Reality |
|---|---|
| "Off" means lower dose | No. Off means zero. |
| "I'm rotating peptides instead of taking time off" | That's continuous use with extra steps. Not the same as cycling. |
| "I just need a 1-2 week mini-break" | Doesn't restore baseline for most classes. Counterproductive. |
| "I can stay on if I lower the dose" | Sometimes (low-dose Sermorelin, topical GHK-Cu). Not for most strength peptides. |
For long-acting peptides, the off period needs to account for half-life. CJC-1295 DAC has a ~7-day half-life — the first 4-5 weeks of "off" are the peptide clearing. An 8-week off period after CJC DAC is really 3-4 weeks of true recovery.
When the off period should be longer
The rules of thumb don't fit every case. Extend the off period if:
- Side effects accumulated during the cycle. A 4-week off period after a glucose-drift cycle of MK-677 won't necessarily restore baseline.
- Bloodwork drifted past acceptable thresholds. Wait for recovery, not just the calendar.
- You ran the high end of the cycle range. A 16-week GH-secretagogue cycle deserves an 8-week off, not 4.
- You're stacking peptides with mismatched cycle lengths. Both have to be zero before counting the off period.
- You had an acute red flag. Off period is irrelevant — the question is whether to ever restart that peptide.
What to do during the off period
The off period isn't passive. See off-cycle strategies for full coverage. Briefly:
- Run end-of-cycle bloodwork
- Document subjective effects without the peptide on board — this is when you find out what the peptide was actually doing
- Don't substitute another peptide just to "stay on something"
- Plan training and life stress to fit the off period
Cumulative-cycle considerations
If you're running multiple cycles per year, the cumulative-exposure question matters more than any single off period. See can I run multiple peptide cycles per year. Annual labs, IGF-1 monitoring on secretagogue stacks, and a yearly extended off period (8-12 weeks) are reasonable defaults for chronic users.